Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: A phase II double-blinded, randomized, dose-escalating trial

Rheumatology

Volumn 41, Issue 10, 2002, Pages 1133-1137

  Choy, E H S ^a,f   Hazleman, B ^b   Smith, M ^b   Moss, K ^c   Lisi, L ^a   Scott, D G I ^d   Patel, J ^e   Sopwith, M ^e   Isenberg, D A ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d NORFOLK AND NORWICH HOSPITAL   (United Kingdom)

^e UCB PHARMA   (Belgium)

^f KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Biologicals; Immunotherapy; Monoclonal antibodies; Polyethylene glycol; Rheumatoid arthritis; Tumour necrosis factor

Indexed keywords

ANTIBIOTIC AGENT; ANTINUCLEAR ANTIBODY; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; ETANERCEPT; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETERIORATION; DISEASE ACTIVITY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MALE; NECK PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; STATISTICAL ANALYSIS; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MIDDLE AGED; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036796777     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Brennan FM, Maini RN, Feldmann M. TNF alpha-a pivotal role in rheumatoid arthritis? Br J Rheumatol 1992;31:293-8.
2. Keffer J, Probert L, Cazlaris H et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10:4025-31.
3. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992;89:9784-8.
4. McKown KM, Carbone LD, Kaplan SB et al. Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis. Arthritis Rheum 1999; 42:1204-8.
5. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
6. Boers M, Tugwell P, Felson DT et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol 1994;41(Suppl.):86-9.
7. Scott DL, Panayi GS, van Riel PL, Smolen J, van de Putte LB. Disease activity in rheumatoid arthritis: preliminary report of the Consensus Study Group of the European Workshop for Rheumatology Research. Clin Exp Rheumatol 1992; 10:521-5.
8. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis [see comments]. Arthritis Rheum 1995;38:44-8.
9. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
10. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
11. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354:1932-9.
12. Elliott MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344:1105-10.
13. Rankin EC, Choy EH, Kassimos D et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995;34:334-42.
14. Maini RN, Elliott MJ, Long-Fox A et al. Clinical response of rheumatoid arthritis to anti-TNF-α monoclonal antibody is related to administered dose and persistence of circulating antibody [abstract]. Arthritis Rheum 1995; 38(Suppl.):S186.